Proton pump inhibitor kidney damage litigation MDL 2789: the $590 million in settlements, the 11,300 cases still pending, the AstraZeneca $425 million resolution, and the Takeda and P&G claims still in play

Proton pump inhibitors are among the most widely used medications in the world. Nexium, Prilosec, Prevacid, Protonix, Dexilant: these acid-reducing drugs have been taken by tens of millions of Americans for heartburn, gastroesophageal reflux disease (GERD), and stomach ulcers. Many were available over the counter, taken daily for years or decades without medical supervision.

The litigation alleges that long-term PPI use causes serious kidney damage, and that the manufacturers knew about the risk and failed to warn consumers. The MDL (In Re: Proton Pump Inhibitor Products Liability Litigation, MDL 2789) in the U.S. District Court for the District of New Jersey before Judge Claire C. Cecchi has been one of the largest pharmaceutical mass torts by case volume: 18,706 cases filed in total, with 11,322 still active as of early 2026.

The litigation has already produced substantial settlements. AstraZeneca (Nexium, Prilosec) settled approximately 11,000 cases for $425 million in October 2023. Combined with settlements from other manufacturers, the aggregate payout has reached approximately $590 million. But the litigation is not over: Takeda (Prevacid) and Procter & Gamble have not reached global settlements, thousands of cases remain pending, and initial settlement distributions only began reaching claimants in late 2025.

What drugs are involved in the PPI kidney litigation and how do they cause damage?

Proton pump inhibitors (Nexium, Prilosec, Prevacid, Protonix, Dexilant) block gastric acid production and were designed for short-term use of 4 to 12 weeks. Prolonged use over years or decades is linked to chronic kidney disease, acute interstitial nephritis, and end-stage renal disease, with studies showing a 20 to 50 percent increased risk of CKD.

Proton pump inhibitors work by blocking the hydrogen-potassium ATPase enzyme system in the stomach's parietal cells, reducing gastric acid production. They are the most potent class of acid-suppressing drugs available and were designed for short-term use (4 to 8 weeks for healing of gastric and duodenal ulcers, 8 to 12 weeks for erosive esophagitis).

In practice, many patients took PPIs continuously for years or decades, often without periodic reassessment of whether the medication was still needed. The widespread availability of over-the-counter formulations (Prilosec OTC, Nexium 24HR, Prevacid 24HR) contributed to long-term unsupervised use.

The alleged kidney injuries include chronic kidney disease (CKD), a progressive loss of kidney function that can ultimately require dialysis or kidney transplant; acute interstitial nephritis (AIN), inflammation of the kidney tissue that can cause sudden kidney damage; acute kidney injury (AKI), a rapid decline in kidney function; and end-stage renal disease (ESRD), complete or near-complete kidney failure requiring dialysis.

A 2016 study published in JAMA Internal Medicine found that PPI users had a 20-50% increased risk of chronic kidney disease compared to non-users. The risk increased with longer duration of use, higher doses, and the absence of a clear medical indication for the medication. Subsequent studies confirmed and refined these findings, establishing the epidemiological basis for the litigation.

The plaintiffs allege that manufacturers, particularly AstraZeneca (which dominated the PPI market with Nexium and Prilosec), knew about the kidney risks as early as 2004 but did not adequately warn consumers or healthcare providers for a decade.

What is the $425 million AstraZeneca PPI settlement?

AstraZeneca agreed in October 2023 to pay $425 million to resolve approximately 11,000 Nexium and Prilosec kidney damage cases in MDL 2789. Individual payouts range from $20,000 to over $150,000 depending on injury severity. Initial distributions began in late 2025, with only about 5% of active cases fully paid as of March 2026.

In October 2023, AstraZeneca announced a $425 million settlement to resolve approximately 11,000 Nexium and Prilosec kidney damage cases in the MDL. The settlement was announced days before the first bellwether trial (James Reider v. AstraZeneca Pharmaceuticals LP, et al.) was scheduled to begin on October 10, 2023.

The settlement resolved the largest block of cases in the MDL, as AstraZeneca was the manufacturer of both Nexium (esomeprazole) and Prilosec (omeprazole), the two most widely used PPIs.

Settlement payouts have ranged from $20,000 to over $150,000 per case, depending on the severity of the kidney injury, the duration of PPI use, the strength of the causation evidence, and other case-specific factors. Initial distributions began in late 2025, with 653 cases fully resolved and paid as of March 2026 (approximately 5% of the active caseload).

The slow pace of distribution is common in large pharmaceutical mass torts: administrative processing, claims verification, and the volume of cases all contribute to extended timelines. Earlier filers have generally received payouts sooner.

Which PPI manufacturers have not settled?

Takeda (Prevacid) and Procter & Gamble (Prilosec OTC and other over-the-counter formulations) have not reached global settlements as of 2026. AstraZeneca resolved the largest block at $425 million, while Pfizer/Wyeth and GlaxoSmithKline contributed to aggregate settlements. Combined payouts across all defendants total approximately $590 million.

The AstraZeneca settlement resolved the largest block, but the litigation continues against other manufacturers:

The combined settlements across all defendants total approximately $590 million. The remaining claims against Takeda and P&G represent a substantial tail of the litigation.

What is the FDA warning timeline for PPI kidney risks?

The FDA issued incremental safety communications about PPI kidney risks between 2010 and 2017, covering hypomagnesemia, acute interstitial nephritis, bone fractures, and chronic kidney disease. Plaintiffs allege AstraZeneca knew of kidney risk data as early as 2004 but failed to update drug labels for approximately a decade, forming the central failure-to-warn claim.

The FDA's response to the kidney risk accumulated gradually, following the same pattern seen in the fluoroquinolone antibiotic litigation: scientific evidence emerged, warnings accumulated, and the allegations center on the gap between when the manufacturers knew and when consumers were told.

2010: The FDA issued an initial safety warning about the risk of hypomagnesemia (dangerously low magnesium levels) with long-term PPI use, which can contribute to kidney injury.

2014: Studies began linking PPI use to acute interstitial nephritis, a specific form of kidney inflammation.

2016: The landmark JAMA Internal Medicine study established the 20-50% increased CKD risk for long-term PPI users, providing the epidemiological foundation for the litigation.

2016-2017: The FDA issued safety communications about the risks of long-term PPI use, including bone fractures, Clostridium difficile infection, and kidney disease.

2022: A meta-analysis in the American Journal of Clinical Oncology found that PPI use increases the risk of certain cancers, including stomach cancer, adding another category of potential injury.

The plaintiffs allege that AstraZeneca was aware of kidney risk data as early as 2004 (through its own clinical trials and post-marketing surveillance) but did not adequately update the drug labels for approximately a decade. The label delay is the central failure-to-warn allegation.

What types of kidney injury are linked to PPI use?

PPI-related kidney injuries range from acute interstitial nephritis (potentially reversible inflammation) to chronic kidney disease Stages 3 through 5, acute kidney injury, and end-stage renal disease requiring dialysis or transplant.

The kidney injuries in the PPI litigation fall along a spectrum of severity, which directly affects case valuation:

The $20,000-$150,000+ range in the AstraZeneca settlement reflects this severity spectrum.

Who is eligible to file a PPI kidney damage claim?

Eligible claimants used a proton pump inhibitor (Nexium, Prilosec, Prevacid, Protonix, Dexilant, or generics) for an extended period, typically more than one year, and were subsequently diagnosed with CKD, AIN, AKI, or ESRD confirmed by medical records. They must show a temporal link between PPI use and kidney injury onset without a predominant alternative explanation.

The PPI kidney litigation applies to individuals who:

Used a proton pump inhibitor (Nexium, Prilosec, Prevacid, Protonix, Dexilant, or generic equivalents) for an extended period (typically more than one year, though shorter-duration claims exist for AIN).

Were subsequently diagnosed with a kidney injury (CKD, AIN, AKI, or ESRD) confirmed by medical records (lab results showing elevated creatinine, reduced GFR, kidney biopsy, or dialysis records).

Can establish a temporal relationship between the PPI use and the kidney injury onset (the kidney diagnosis postdates the PPI use, and there is no alternative explanation for the kidney disease).

Alternative explanations that the defendants raise include diabetes, hypertension, and other conditions that independently cause kidney disease. The strongest PPI cases involve patients without these confounding conditions, where the PPI use is the most plausible cause of the kidney injury.

How do PPI cases compare to other mass torts?

The PPI MDL 2789 is among the largest pharmaceutical mass torts with 18,706 cases filed and $590 million in aggregate settlements. It shares the failure-to-warn theory and delayed FDA action pattern seen in fluoroquinolone, Zantac, and Depo-Provera litigation, but is distinctive for its case volume and the substantial settlements already paid while claims against non-settling defendants remain active.

The PPI litigation shares features with several Halstonberg-covered mass torts:

The PPI litigation is distinctive in its size (18,706 cases filed), the substantial settlement amounts already paid ($590 million aggregate), and the ongoing nature of the claims against non-settling defendants.

What should PPI kidney damage claimants do now?

The PPI kidney litigation is still accepting new cases as of 2026. Claims against Takeda (Prevacid) and P&G (OTC formulations) remain active and may produce separate settlements. Key evidence includes pharmacy records of long-term PPI use, medical records confirming kidney diagnosis, and a clear temporal link. Earlier filing is advantageous given slow distribution timelines.

For someone who used a PPI long-term and developed kidney disease:

The litigation is still accepting cases, though the AstraZeneca settlement has resolved the largest block. Claims against Takeda (Prevacid) and P&G (OTC formulations) remain active.

The key evidence: medical records documenting the kidney diagnosis (CKD, AIN, AKI, or ESRD), pharmacy records establishing long-term PPI use (duration and which specific PPI product), and the temporal relationship between the PPI use and the kidney injury onset.

Earlier filing is advantageous. Settlement distributions have been slow (5% of active cases paid as of March 2026), and earlier filers have generally been processed sooner. There is also a risk that settlement funds could become limited as more claims are processed.

If you used Nexium or Prilosec specifically, the AstraZeneca settlement is the applicable framework. If you used Prevacid (Takeda) or an over-the-counter PPI from P&G, the claims against those manufacturers are still pending and may produce separate settlements.

The statute of limitations varies by state and depends on when the plaintiff knew or should have known of the connection between the PPI use and the kidney injury. The "discovery rule" is critical: for many patients, the connection was not apparent until years after the kidney disease was diagnosed.

Consult with a mass tort attorney who is actively working in MDL 2789. The settlement infrastructure is established for AstraZeneca cases, and the claims process has specific requirements and deadlines.

For patients with documented long-term PPI use and subsequent kidney disease, the settlement framework provides a structured path to compensation, though the pace of distribution means patience and prompt filing are both important.

This article is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for guidance on your specific situation.